aTyr Pharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATYR Nasdaq 2836 atyrpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for aTyr Pharma, Inc.

aTyr Pharma Announces Research Collaboration with Montefiore Einstein - Oct 19th, 2026 5:00 am
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry - Oct 13th, 2026 6:00 am
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - Sep 24th, 2026 11:31 am
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis - Sep 24th, 2026 8:59 am
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - Sep 24th, 2026 4:00 am
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight - Sep 8th, 2026 8:31 am
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - Sep 1st, 2026 2:36 pm
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Aug 7th, 2026 2:39 pm
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - Aug 7th, 2026 2:01 pm
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 - Jul 15th, 2026 6:00 am
What It Means To Hold Moderna Stock In A Crash - Jul 13th, 2026 7:12 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - May 15th, 2026 6:00 am
aTyr Pharma to Participate in Upcoming Investor Conferences - May 13th, 2026 2:01 pm
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial - May 11th, 2026 6:09 pm
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting - May 11th, 2026 2:01 pm
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - Apr 8th, 2026 11:00 am
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - Mar 12th, 2026 6:03 am